Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 November 2019 | Story Valentino Ndaba | Photo Charl Devenish
SK Luwaca at UFS Safety Summit for off-campus students
Sikhululekile Luwaca, leader of the UFS Safety Champions, addresses a delegation at the Higher Education Safety Summit from 18-19 October 2019 at the Bloemfontein Campus.

A meeting of minds over student safety recently took place at Kovsies. The Higher Education Safety Summit saw a cohort of 165 students from the University of the Free State (UFS), Central University of Technology and Sol Plaatje University, collaborating with the heads of Protection Services from the respective institutions to devise a safety blueprint specifically focusing on the off-campus environment.

“The rental tribunal came on board to assist with rental disputes between students and landlords, in addition to accreditation issues being discussed,” Sikhululekile Luwaca, former SRC President of the Bloemfontein Campus and leader of the UFS Safety Champions that form part of the Unit for Institutional Change and Social Justice.

Luwaca further said that the Mangaung Metropolitan Municipality also committed to assist the universities in addressing crime and enforcing by-laws. “A strategic safety plan was developed around spatialisation and zoning of student communes, developing a system that will assist universities to establish where students stay by using technology such as geographic information system (GIS),” he added.

What were the objectives of the summit?
Being the first of many to come, the summit set out clear objectives which all stakeholders have committed to work tirelessly to achieve, both in the short and long term.

The goals of the summit were threefold. Firstly, the intention was to build capacity between students and staff of all institutions involved to implement programmes by transferring the skills and knowledge between one another.

Secondly, the idea was to gather and consolidate input from the various higher-learning institutions and by so doing diversify the solutions. Thirdly, the purpose of the summit was to create an official platform where partners may consult on interventions that will ripple from the local, to the provincial and further to national level.

Andiswa Msomi, Spatialisation Group Leader and the Safety Champions’ administrator said she appreciated the shift in perspective that the summit brought. “The summit brought to my attention that sometimes we focus so deeply on one aspect of a problem that we end up not seeing alternative solutions. Due to active participants, new solutions came up, new ideas were brought forth and more importantly, we were able to get other institutions on board,” she said.

What are some of the tangible outcomes?
Going forward, an internal report which focuses on crime prevention measures will be presented to all UFS stakeholders. An external report, which will be submitted by the Safety Champions to the government in January 2020, is expected to be integrated into the Provincial Crime Prevention Strategy.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept